Navigation Links
CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Date:8/22/2007

Side Effect Profile and Tolerability of Regadenoson Myocardial Perfusion Scintigraphy in Women; Poster, Tuesday, September 4, 2:00 - 6:00 p.m. CEST

Superior Safety Profile of Regadenoson Versus Adenosine in Patients with Chronic Obstructive Pulmonary Disease Undergoing Radionuclide Myocardial Perfusion Imaging; Poster, Tuesday, September 4, 2:00 - 6:00 p.m. CEST

In addition, on Tuesday, September 4, CV Therapeutics is sponsoring an EBAC (European Board for Accreditation in Cardiology) educational program, Targeting Myocardial Ischaemia-Future Opportunities for Improved Outcomes, chaired by Dr. Phillip Poole-Wilson of the United Kingdom and Dr. Eugene Braunwald of the United States. On Monday, September 3, CV Therapeutics is sponsoring a FOCUS Cardiology Practice Session, Chronic Stable Angina Management.

Additional information regarding the ESC Congress 2007 can be accessed at http://www.escardio.org

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT- 6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or e
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 The board of directors of ... today declared a dividend for the first quarter of ... ,, The dividend is payable March 10, ... business on ,, February 12, 2010. ,, Lilly, ... of pharmaceutical products by applying the latest research from ...
(Date:12/14/2009)... CHICAGO, Dec. 14 Sword Diagnostics, Inc. ... Patent Office (USPTO) has issued patent number ... Biological Organisms using Raman Scattering" to the company. ... on improved sensitivity. ,, "The issuance of ... move forward with our continued development and commercialization," ...
(Date:12/14/2009)... DIEGO, Dec. 14 Cardium Therapeutics (NYSE ... "Phase 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the ... Wound Healing: Science and Industry Conference held December ... The conference is attended by top industry ... advanced wound healing. Dr. Barbara K. Sosnowski, ...
Breaking Medicine Technology:Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4President Bill Clinton to Deliver Keynote Address at 5th Annual World Healthcare Innovation and Technology Congress November 10 2009 Washington D 49654 1President Bill Clinton to Deliver Keynote Address at 5th Annual World Healthcare Innovation and Technology Congress November 10 2009 Washington D 49654 2President Bill Clinton to Deliver Keynote Address at 5th Annual World Healthcare Innovation and Technology Congress November 10 2009 Washington D 49654 3Dragon Pharma Announces Results of 2009 Annual General Meeting 12730 1Sparta Systems Unveils TrackWise 28R 29 Clinical Quality Management Solution 49652 1Sparta Systems Unveils TrackWise 28R 29 Clinical Quality Management Solution 49652 2Sparta Systems Unveils TrackWise 28R 29 Clinical Quality Management Solution 49652 3
(Date:12/14/2009)... men whose disease had been treated, hadn,t spread, study ... appears to reduce the risk of death in male ... began in January 1986, included 668 men who,d been ... colon cancer that had not spread (nonmetastatic cancer). Every ... them about any new cancer and disease diagnoses, as ...
(Date:12/14/2009)... But the bump in odds is small and shouldn,t ... (HealthDay News) -- Older women who take antidepressants may ... stroke and death compared to women not on the ... can be different from clinical significance," stressed Dr. Jordan ... Medical School, and lead author of a report in ...
(Date:12/14/2009)... of scientists from the UC San Diego School of ... protein switch that helps prevent liver damage, including inflammation, ... understanding of how the protein, TAK1, works could lead ... and cancer. , "TAK1 appears to be a ... MD, professor of medicine and Dean of the UC ...
(Date:12/14/2009)... highly stigmatized, according to psychiatrists Charles F. Zorumski, ... these Washington University physicians have written a book ... Zorumski and Rubin, who have more than 50 ... patient families, say some of the problems related ... lack of understanding psychiatry and what psychiatrists can ...
(Date:12/14/2009)... mental functioning , , , MONDAY, Dec. 14 (HealthDay News) ... to live longer than those who look older than ... came from research that involved 1,826 Danish twins, aged ... tests and then had their faces photographed. Three groups ... age they perceived the participants to be. Twins were ...
Breaking Medicine News(10 mins):Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3Health News:Scientists uncover protective mechanism against liver cancer 2Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3Health News:Looking Younger Than Your Age May Mean Longer Life 2
... tend to have near normal lung function and seem ... male lung cancer patients//. Similarly, male lung cancer patients ... pulmonary disease, which is characterized by progressive deterioration in ... published in the CHEST journal, a publication of the ...
... Health insurance plans show wide variations among different states ... // ,-Employees in the smallest firms (1-9 ... premiums than those in the largest firms (1,000+ workers), ... by a health plan--is taken into account, a new ...
... drug that can treat breast cancer. But NHS said that it ... breast cancer. // Due to this there are lots of legal ... to pay for the drug. The latest being a British man, ... told that his local NHS trust would fund for his treatment ...
... the health service is losing more than ?50m because of ... years of similar complaint by NHS managers the situation is ... in Huntingdon said: ‘Some people do not turn up as ... us a lot of problems in lost capacity and extra ...
... A recent study has revealed that heart patients who are ... of receiving a jolt from these devices to bring their ... ,The study was conducted at Washington University School ... are related to smoking, and previous studies have shown that ...
... doubts about the effect of these supplements. This is a ... This is produced naturally by the body at night. When ... trails says that it is not very effective in the ... melatonin has the same sleep-inducing effect in the night. The ...
Other Medicine News:Health News:Male Lung Cancer Patients Less Likely To Perform Well in Lung Function Tests 2Health News:Health Insurance Plans Varies among States 2Health News:Health Insurance Plans Varies among States 3Health News:Jolt to Quit Smoking 2
... disposable pH catheter is used by ... for evaluating acid reflux events., ... pH monitoring. , ,Alpine's VersaFlex ... catheter on the market (4.7 French), ...
... pH catheters are efficient, economical, eliminate ... greater patient comfort during the test ... systems have been designed to use ... accurate room-temperature calibration. The temperature correction ...
FLEXILOG accessory....
FLEXILOG spare part....
Medicine Products: